Abstract Experimental and clinical studies have clearly shown the role of the sympathetic nervous system in the pathophysiology of several cardiovascular and non-cardiovascular diseases. This short review will be aimed at focusing and discussing the new information collected on two specific clinical conditions such as obesity and metabolic syndrome. The paper will briefly describe the four main mechanisms that represent the common link between these two pathophysiological conditions and that through the sympathetic nervous system contribute to increase the cardiovascular risk.
Introduction
The metabolic syndrome is characterized by the simultaneous occurrence of metabolic abnormalities including obesity, glucose intolerance, dyslipidemia and hypertension, that result in a marked increase in cardiovascular morbidity and mortality [1] . High blood pressure is a classical feature of the metabolic syndrome and it has been reported that the metabolic syndrome is present in up to 30 % of hypertensive patients [2] . Therefore, high blood pressure is included in the definition for the metabolic syndrome. This is also the case for obesity and in particular for visceral fat excess distribution. Obesity is much more than a cosmetic issue given its association with poor quality of life and reduced life expectancy [3] . In addition, obesity related illness place a considerable burden on the economy by increasing rates of health care usage and associated costs. The sympathetic nervous system plays an important role in the regulation of metabolic and cardiovascular homeostasis. The sympathetic nervous system activation is characteristic of a number of metabolic and cardiovascular disorders, many of which occur more frequently in obese individuals. Obesity potentiates sympathetic nervous system activation in patients with hypertension [4] and heightened sympathetic nervous system activity is associated with adverse clinical outcomes [5] .
The present review will examine the role of the sympathetic nervous system in the development of the haemodynamic and metabolic abnormalities occurring in obesity and metabolic syndrome. We will also provide a brief overview of the mechanisms potentially responsible for the neuroadrenergic alterations described in these pathophysiological conditions.
The Metabolic Syndrome: Definition
This condition is characterized by various combinations of abnormalities in body weight, glucose metabolism, lipid metabolism, and blood pressure. Several definitions were used to characterize it [6, 7] , but it is now universally referred to as ''metabolic syndrome'', a definition proposed by the US National Cholesterol Education Program Adult Treatment Panel III (ATP III) [1] . It requires the presence & Gino Seravalle g_seravalle@yahoo.com of at least three of the following factors for diagnosis: waist circumference greater than 102 cm in men and 88 cm in women, elevated plasma triglycerides levels (C150 mg/ dL), reduced high-density lipoprotein (HDL) cholesterol (\40 mg/dL in men and \50 mg/dL in women), elevated fasting glucose (C110 mg/dL), and blood pressure in the high-normal (C130 mmHg systolic or C85 mmHg diastolic) or hypertensive range. The application of this definition allows us to observe in the population that the metabolic syndrome is so widespread because it affects approximately one of five individuals. It is common in both genders and all ethnic groups, with a high prevalence observed in both developed and developing countries from all continents and a peak of prevalence in middle-aged and elderly individuals [8, 9] but with new emerging alert for increased prevalence also in younger individuals [10] . The definition of metabolic syndrome is under revision after several suggested modifications: (a) to lower the cutoff blood glucose value to 100 mg/dL or lower, (b) to consider a waist circumference greater than 94 cm in men and 80 cm in women associated with two other criteria selected from an elevated fasting glucose (C100 mg/dL), a low LDL cholesterol level, an elevated triglyceride level, and a high-normal blood pressure, and (c) to include detailed lipoproteins abnormalities and proinflammatory or thrombotic factors [11] . At present, the ATP III definition is the preferred choice, even when the definition recently proposed by the International Diabetes Federation [11] is taken into account.
Several mechanisms are postulated as the major determinants of the syndrome. These include genetic factors, insulin resistance, atherogenic dyslipidemia, visceral obesity, and chronic low-grade inflammation [12] [13] [14] . It is likely that the previously described factors may interact with each other, making the pathophysiological aspect difficult to be separately analyzed [15] . The hypothesis is that all the previously mentioned mechanisms have a common pathogenetic background in the sympathetic nervous system activation [16, 17] .
3 The D-4 Figure 1 show the ''dangerous four'' (D-4) that is the four pathophysiological determinants contributing to the hyperadrenergic state in both obesity and metabolic syndrome.
The sympathetic nervous system has a main role in maintaining the physiological homeostasis of the cardiovascular system. For this action the sympathetic nervous system is modulated by different mechanisms: (a) hormonal (renin-angiotensin-aldosterone system, cortisol, vasopressin, growth hormone, asymmetric dimethilarginine, endothelin, gonadic hormones), (b) metabolic (insulin, leptin, free fatty acids), (c) reflex (baroreceptors, cardiopilmonary receptors, chemoreceptors), (d) inflammatory (ROS system, cytokines), and (e) endothelial and hematologic. Each component of the D-4 will be briefly analyzed to discover their role in the increasing cardiovascular risk.
Abdominal Obesity
The hypothesis that a functional alteration of the sympathetic nervous system might represent the pathophysiological cause of the metabolic syndrome is based on the evidence that the two main variables which appear to be primitively deranged in this condition, i.e. blood pressure and thermogenesis, are under adrenergic influences [17] . A wide range of information has already shown that the obese state, even when not accompanied by a blood pressure elevation, displays signs of adrenergic activation, such as an increased resting heart rate values and elevated plasma norepinephrine values [18] . This has been confirmed by the results of the Normative Aging Study, which has shown in a large number of subjects a close direct relationship between 24-h urinary norepinephrine metabolities and body mass index values [19] . This has also been confirmed by the evidence that an augmented sympathetic neural discharge to skeletal muscle as well as an increased spillover rate of norepinephrine from sympathetic nerve endings, particularly at the level of the kidney, takes place in obese normotensive subjects [20, 21] . Taken together, these findings provide conclusive evidence that the sympathetic overdrive plays a role in human obesity, although the magnitude of this role differs somewhat according to the specific patterns of fat distribution. The results of microneurographic studies assessed in abdominal and peripheral obesity have clearly shown that the degree of sympathetic activation (and the magnitude of the insulin resistance state) is much greater in patients with visceral body fat deposits than in those with peripheral distribution of adipose tissue [22] . This finding has been further confirmed by the results of a study showing that subcutaneous body fat accumulation is not linked to an adrenergic overdrive [23] . Several data have shown that also metabolic syndrome is accompanied by an hyperadrenergic state that is independent of the presence of hypertension [24, 25] and that can contribute to complicate hyperadrenergic conditions like congestive heart failure [26] .
Insulin and Leptin
Insulin resistance and hyperinsulinemia are important in the metabolic syndrome. Indeed, elevated plasma insulin levels may account for many of the feature of the metabolic syndrome since insulin has been demonstrated to alter both glucose and lipid metabolism, to enhance atherogenesis, to increase blood pressure [7, 16] . Human studies indicate that the sympathetic response triggered by insulin is heterogeneous. While muscle sympathetic nerve activity is increased following acute hyperinsulinemia [27, 28] , renal norepinephrine spillover remains unchanged [28] and no association has been observed between hyperinsulinemia and the rate of renal norepinephrine spillover to plasma in obese [21] . Given that obesity and hypertension are accompanied by high rates of norepinephrine spillover from the kidneys [21, 29] it would seem that the mechanisms underpinning the increased sympathetic nerve outflow in obesity and metabolic syndrome are not confined to hyperinsulinemia. In the human forearm, increased norepinephrine release results in a reduction in forearm blood flow and is associated with reduced forearm uptake of glucose, highlighting the adverse effect of sympathetic activation on the ability of the cell to transport glucose across its membrane, which in turn is a hallmark of insulin resistance [30] .
Several studies have also provided that high plasma leptin concentrations may drive the sympathetic activation in obesity [25, 31] . Similarly, in subjects with the metabolic syndrome it has been observed that fasting plasma leptin levels and whole-body insulin sensitivity index are both significantly correlated with the rate of norepinephrine spillover to plasma but not to MSNA [32] . One argument against leptin-mediated increase in sympathetic nervous activity is that leptin gene expression is higher in subcutaneous than in visceral adipose tissue [33] while sympathetic nerve traffic is not elevated in subjects with subcutaneous obesity even though plasma leptin levels are higher [23] . Recent studies also suggest that the brain renin-angiotensin system (RAS) mediates the actions of leptin on renal and brown adipose tissue thermogenic sympathetic nerve activity without affecting leptin actions on food intake. These observations suggest that increases or decreases in activity of the brain RAS could modulate the effects of leptin on energy expenditure and blood pressure without influencing leptin-induced decreases in food intake. There is evidence that genetic variants in the leptin receptor affect sympathetic activity and blood pressure in humans, but studies have failed to show an increase in blood pressure with administration of leptin [34] .
Reflex Impairment
The changes observed in sympathetic drive, such as those described in the metabolic syndrome and in its single components, are likely to have a multiple pathophysiological nature. One of the hypotheses advanced is that the neurogenic alterations originate from an impairment of the baroreflex (i.e. a major restraining mechanism on sympathetic tone) [25, 35] . This has been confirmed by the evidence that arterial baroreceptor control of sympathetic nerve traffic undergoes a clearcut impairment in patients with metabolic syndrome and that both the sympathoinhibitory and the sympathoexcitatory baroreflex components are involved [25] . The reflex impairment may also involve other reflexogenic areas, such as the cardiopulmonary receptors and the chemoreceptors as well [25] . Although no specific data are available on the behaviour of these reflex functions in the metabolic syndrome, data collected in hypertensive patients with left ventricular hypertrophy or in obese subjects with sleep apnea syndrome do provide evidence that alterations in the reflex restraint exerted by these reflexogenic areas on adrenergic drive may participate in the occurrence of the hyperadrenergic state [36, 37] . 
RAAS and Oxydative Stress
Obesity is associated with activation of the renin-angiotensin-aldosterone system. The results of animal studies indicates that angiotensin II can act centrally to increase sympathetic nervous system activity [38] . It has also been shown in humans that angiotensin II infusion could increase sympathetic nerve traffic while angiotensin converting enzyme inhibitor reduces it [39] . Furthermore, multiple components of the renin-angiotensin system are expressed in adipose tissue and angiotensinogen is expressed to a greater extent in visceral compared with subcutaneous adypocytes [40] . Thus, increased circulating levels of angiotensin II could contribute to sympathetic activation in visceral obesity. This is confirmed by the observation that angiotensin II receptor blockade reduces sympathetic nerve traffic in obese hypertensive humans [41] . The chronic hypoxia of visceral fat lead to up-regulation of the renin-angiotensin system and down regulation of nitric oxide synthases [42] . Hypoxia may lead to sympathoexcitation via two mechanisms: augmentation of peripheral chemoreflex sensitivity and direct effects on sites of central regulation. Human studies have shown that hypoxia increases sympathetic activity, blood pressure levels, antifibrinolytic activity (elevation in plasminogen activator inhibition type 1), oxidative stress (activation of reduction-oxidation-sensitive gene expression is suggested by the increase in some protein products of these genes, including vascular endothelial growth factor, erythropoietin, and endothelin-1), inflammatory mediators (tumor necrosis factor-a, interleukin 6, T lymphocyte, and pentraxin), and hypercoagulability [4, 43, 44] .
Conclusions
In recent years the relationships among sympathetic dysfunction, obesity and complicated obesity, and the cardiovascular risk have engendered much interest. As a result, sympathetic overactivity is increasingly being considered a major target for therapeutic interventions aimed at reducing global cardiovascular risk.
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